We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ELFABRIO (Chiesi Australia Pty Ltd)
Product name
ELFABRIO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
174 (255 working days)
Active ingredients
pegunigalsidase alfa
Registration type
NCE/ NBE
Indication
ELFABRIO is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.